

ONLINE SUPPLEMENTARY MATERIALS

Supplementary table 1: Main symptoms consistent with COVID-19 in the study sample.

Symptoms	IFX (n=69)	RTX (n=121)	P value
Flu-like symptoms	9(13.0%)	4(3.3%)	0.016
– Dyspnea	5 (7.2%)	6(5.0%)	0.532
– Ageusia	9 (13.0%)	9 (7.4%)	0.210
– Anosmia	2 (2.9%)	4(3.3%)	1.00
– Fever	7(10.1%)	7(5.8%)	0.387
– Headache	4(5.8%)	5(4.1%)	0.726
– Asthenia	2(2.9%)	2 (1.7%)	0.622
– Cough	9(13.0%)	8(6.6%)	0.185
– Diarrhea	1 (1.4%)	2(1.7%)	1.00
– Sore throat	3(4.3%)	5(4.1%)	1.00

Legend: IFX = Infliximab. RTX = Rituximab

Supplementary table 2: Main symptoms consistent with COVID-19 in the validation cohort.

Characteristics	IFX (n=112)	RTX (n=94)	P value
Symptoms compatible with COVID-19 (%)	53 (47.3)	43 (45.7)	0.889
Hospitalisation (%)	0 (0.0)	3 (3.2)	0.093
Symptoms reported (%)	112 (100.0)	94 (100.0)	NA
– Fever (%)	19 (17.0)	13 (13.8)	0.568
– Rhinitis (%)	35 (31.2)	25 (26.6)	0.539
– Cough (%)	25 (22.3)	19 (20.2)	0.736
– Muscle aches (%)	21 (18.8)	15 (16.0)	0.713
– Headache (%)	31 (27.7)	20 (21.3)	0.332
– Fatigue (%)	32 (28.6)	21 (22.3)	0.340
– Diarrhoea (%)	9 (8.0)	7 (7.4)	1.000
– Dyspnoea (%)	14 (12.5)	8 (8.5)	0.377
– Sore throat (%)	26 (23.2)	23 (24.5)	0.870

Legend: RTX=Rituximab, IFX= Infliximab